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Abstract
Background: Cancer survivorship has increasingly become the focus of research due to progress in early detection
and advancements in the therapeutic approach, but high-quality information sources for outcomes, potential
confounders and personal characteristics present a challenge. Few studies have collected breast cancer care data
from mixed data sources and validated them, and to the best of our knowledge, none so far have been conducted
in Israel, where National Health Insurance Law assures universal health care, delivered through four health care
funds with computerized administrative, pharmaceutical and medical databases.
This validation study is aimed to assess the accuracy and completeness of information on cancer care and health
outcomes using several research tools, before embarking on a full-scale study aimed to evaluate the long-term
treatment-related health adverse outcomes in a cohort of breast cancer survivors.
Methods: One hundred twenty randomly sampled female patients diagnosed with primary breast cancer in years
2000–2010 in northern Israel, who are members of the “Leumit” healthcare fund, were included. Data sources
included “Leumit” medical records, the National Cancer Registry and a self-report questionnaire. The questionnaire
was completed by 99 % of the women contacted. The accuracy of the information regarding cancer care was
assessed with the reference standard set as one of the research tools, varying per the characteristic being under
investigation. For example: health outcomes and medical history were validated against “Leumit” medical records,
while construct validity of the self-reported questionnaire served to assess the prevalence of chronic pain.
Agreement, predictive values, correlations, and internal consistency were calculated. Logistic regression models
were constructed to assess potential predictors of correct responses.
Results: The overall level of agreement (Kappa) was almost perfect for demographics and outcomes, above 0.8 for
treatments and chronic pain, while only fair to moderate for most of the self-reported medical history. Correct
responses of medical history were associated with Jewish ethnicity, recency of breast cancer diagnosis, and family
history of cardiovascular disease. The internal consistency of the quality-of-life scale was above 0.9.
Conclusion: In the absence of a national registry for cancer care, a mixed methodology for data collection is the
most complete source.
Trial registration: Trial registration number Not available. This is an observational study with prospective data
collection and no intervention; therefore, trial registration number is not required.
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Background
Cancer survivorship has increasingly become the focus
of research due to progress in early detection and ad-
vancements in the therapeutic approach. The goal of
survivorship research is to understand, and thereby re-
duce, the adverse outcomes of cancer diagnosis and
treatment [1]. Breast cancer survivors may develop late
treatment-induced organ damage and functional disabil-
ities, and many of them are likely to suffer from unen-
durable chronic pain which might irreversibly alter the
quality of their lives. To effectively conduct a survivor-
ship study, one is in need of information on potential
adverse outcomes, explanatory variables, such as cancer
clinical characteristics and primary treatment, as well as
potential confounders, including sociodemographic fac-
tors, lifestyle and health behavior. Good and valid infor-
mation on all of these variables is, in fact, a challenge.
Medical records have frequently been considered the
“gold standard” means for retrieving detailed breast can-
cer clinical information; however, this method of data
collection, especially if not fully digitalized, can be ex-
pensive, time-consuming and labor intensive [2–4]. In
contrast, administrative claim databases, are easier to
obtain, but are valid only when payment is not bundled
[4] and covered services have specific codes for reim-
bursement. However, both medical records and adminis-
trative claims were not primarily intended to be used for
research or surveillance purposes, and accordingly their
quality of data is oftentimes questioned [5].
Cancer registries, on the other hand, have been de-
signed specifically for epidemiological research and can-
cer control. Completeness of breast cancer case-finding
has been shown to be very high, yet the validity and
completeness of cancer registry care data have not been
well-established [6].
Self-report questionnaires have been adopted as a
more feasible option for obtaining information on cancer
treatment [2, 7] but the appraisal of cancer long-term
impact on the quality of life of breast cancer survivors
has not been commonly prioritized in these surveys.
Linking these diverse but complementary data sources
can provide unique cancer care information, provided
the collected data are complete and valid [8, 9]. To date,
few studies have invested time and effort in gathering
comprehensive breast cancer care data from mixed
sources [10], and even fewer have endeavored to validate
these data so to avoid disseminating erroneous informa-
tion in the clinical setting [2, 3]. To the best of our
knowledge, none of these validation studies were carried
out in Israel, where National Health Insurance Law as-
sures universal healthcare, delivered through four
healthcare funds.
The objective of the present feasibility study was to as-
sess the validity of several research tools in reporting
information on breast cancer care and certain health
outcomes and to identify potential sources of bias in
outcome estimation [11] before embarking on a full-
scale study intended to evaluate the long-term treatment




Subjects of this feasibility study were female members of
Leumit Health Services (LHS), a nonprofit Israeli health
maintenance organization (HMO). All enrolled participants
were breast cancer patients, at least one-year survivors,
who were treated for early-stage or regionally advanced in-
vasive breast cancer between January 1, 2000 and Decem-
ber 31, 2010. The upper limit of study entry was set to
2010 to guarantee that the follow-up period was extended
sufficiently (at least five years) to capture adverse outcomes
that are associated with long latency periods.
Patient medical record stored at LHS was used to identify
patients with a diagnosis of first primary breast cancer (clas-
sified according to the International Classification of dis-
eases, Ninth Revision (ICD-9) codes: 174 (174.0-174.9)). An
approximate 20 % random sample of all women diagnosed
with breast cancer and treated in Rambam Medical Center,
a healthcare tertiary hospital located in the Israeli northern
district, was selected using a sampling strategy stratified by
year of diagnosis. The rationale for restricting our study
population to a single institution was twofold: First, inas-
much as the objective of the full-scale study is to evaluate
cancer treatment impact on health of breast cancer survi-
vors, the element of variance in distribution of treatments
among study population is of central importance. Rambam
Medical Center, which is the only institution in the north of
Israel that offers combined treatment for breast cancer ac-
cording to a standard protocol, was therefore an ideal
choice. Secondly, we intended to estimate the degree of
Hebrew comprehension among the Arab participants,
whose majority resides in the north of the country, as this
language was used in the delivery of the questionnaire.
The initial eligibility screen identified 120 patients. By
linkage with the Israel National Cancer Registry (INCR),
37 patients were excluded for not meeting the inclusion
criteria. Of the remaining 83 eligible candidates for the
administration of a constructed questionnaire, 15 sub-
jects were not contacted due to death, LHS disenroll-
ment and missing contact information, or degenerative
mental illness, leaving a total 68 women who were con-
tacted. 67 subjects completed the survey (Fig. 1).
Data collection
Self-report questionnaire
A 77-item questionnaire written in Hebrew was devel-
oped to capture information that is not routinely
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registered in administrative databases. The questionnaire
comprised of six main domains: (1) demographics, (2)
lifestyles (3) medical history, (4) reproductive history, (5)
outcome assessment of chronic pain and related seque-
lae, including allodynia, paresthesia, phantom sensations
and fatigue, and (6) quality of life assessment using the
medical outcomes study 36-item short-form health sur-
vey (SF-36) [12].
Questions on demography, medical and reproductive
history, and lifestyles were adapted from the Israeli Na-
tional Health Interview Survey [13]. The questionnaire
did not include items on cancer treatments to avoid rais-
ing the participant's awareness to the main study ques-
tions and thus to keep the respondent bias to a
minimum. Additionally, we do not expect breast cancer
survivors, especially those diagnosed in earlier years, to
recall information pertaining to their treatment.
To assess the appropriateness of the questionnaire,
a two-stage pretest was performed. The first stage
was an individually-based expert review. Three re-
searchers from the academia and the clinical practice
setting conducted independent reviews on the
assigned questionnaire for the appraisal of potential
problems with the data collection instrument, such as
glitches in wording of questions, or need for add-
itional items. A revised version of the instrument was
administered to participants of the current pilot study
in the form of telephone interviews, except for one
face-to-face interview. If pretesting indicated that
there was a low likelihood of obtaining sufficiently
sound and consistent data, troublesome items were
dropped or revised accordingly.
Medical record abstraction from leumit health services
registries
LHS patient data are collected in real time from all
levels of care and automatically stored in the patient
electronic medical record, then downloaded on a daily
basis to LHS central databases. This registry has been
described elsewhere [14]. We used standard data collec-
tion forms to abstract detailed patient information on
demographics, breast cancer characterization and treat-
ments, medical history, medications and supplements,
and vital status. Follow-up information on potential out-
comes included incidence of cardiovascular disease,
osteoporosis, fractures and diabetes, occurring at least
one year post breast cancer diagnosis.
Leumit administrative databases
Breast cancer care data were obtained from three admin-
istrative datasets of LHS: 1) demographic registry; 2)
diagnoses and procedures billing database; and 3) phar-
macy claims. The demographic registry includes basic
demographic and geographic information. The billing
dataset contains information on services, diagnoses, and
procedure interventions encountered from ambulatory
care (same-day surgery, day procedures, emergency de-
partment visits, and community rehabilitation program
services) or inpatient settings, coded using the ICD-9
coding system. The pharmacy dataset includes patient
and prescriber information plus drug and dosing details
(days of supply, quantity, drug name, and medication
class), coded using the anatomical therapeutic chemical
classification system.
Fig. 1 Survey sample flow chart
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Abstraction from Israel National Cancer Registry
INCR is a statutory body in the Israel Ministry of Health
responsible for collecting data on malignant disease inci-
dence since 1960. Cancer reporting by hospitals, path-
ology and cytology laboratories and other health care
providers has been mandatory since 1982. INCR covers
the entire Israeli population, approximating 8.3 million,
and its database is currently complete as of the end of
December 2013 [15]. Demographic and clinical data col-
lected from INCR included: date of birth, ethnicity and
religion, breast cancer diagnosis date, laterality, clinical
stage, and treatments.
Validation procedure
The administrative databases (LHS and INCR) were used
to abstract data on all 119 subjects with breast cancer,
whereas the self-report questionnaire contributed infor-
mation on 67 respondents (see Fig. 1). Comparisons
were confined to shared patients between research tools,
and only patient characteristics shared by more than one
data source were examined for accuracy and complete-
ness. The dataset adopted as the reference standard var-
ied as a function of the characteristic being under
investigation. As for residence, ethnicity and cohabit-
ation status, the directly reported information through
questionnaires was considered the reference standard by
virtue of being the most up to the minute data source.
INCR was used as a reference with respect to mortality,
since this information is routinely routed to INCR via
the Israel National Population Registry; the latter re-
quires by law notification of a resident death occurring
in Israel or abroad. Primacy of data was credited to
INCR as well in relation to breast cancer diagnosis date,
laterality, axillary node dissection, and type of surgery, as
these data originated in the hospital are directly trans-
ferred to INCR. Generally, LHS administrative databases
record such information, however, due to bundled pay-
ment in which hospitals are paid a “lump sum” per pa-
tient regardless of how many tests or treatments the
patient receives [16], there may be at times a paucity of
cancer treatment specific details in LHS claims. LHS
claims were considered the reference standard for adju-
vant therapy considering that LHS is billed specifically
per exploited service, whether it were an administered
drug or the delivery of radiation treatment. INCR may
be lacking such information since hospitals tend to sup-
plement data on initial course of treatment, mostly de-
tails of surgery that is considered the first-line
treatment, while ambulatory services of adjuvant therapy
that are undertaken in later stages are often underre-
ported [6].
LHS individual medical records were reviewed for re-
covering missing information and the ascertainment of
administrative outcome codes and reported medical
history. The diagnostic criteria included discharge sum-
maries, specialist notes, laboratory tests, referrals, signals
and images, medical procedures and prescriptions. In
addition, being an outcome study, it was essential to de-
velop further validation algorithms of administrative
diagnosis codes to guarantee minimal misclassification
of outcome (Table 1). Chronic pain was not validated
against medical charts; its validation was based instead
on degree of concordance with the SF-36 self-reported
measure of pain [17] (item 21: How much bodily pain
have you had during the past 4 weeks?). The 6-response
choices were dichotomized to: none to very mild, and
mild to very severe.
Statistical analysis
Agreement analysis was conducted with analysis re-
stricted to parameters reported in more than one data
source. For dichotomized variables, absolute agreement
or proportion correct was first assessed. Next, Kappa
statistic and 95 % confidence interval (CI) using the
standard normal distribution [18] was used to evaluate
inter-observer agreement. The interpretation of Kappa
statistic was based on the suggested scale by Altman
[19], which categorized the strength of agreement be-
yond chance as Poor (<0.20), Fair (0.21–0.40), Moderate
(0.41–0.60), Good (0.61–0.80) and Very good (0.81–
1.00). Where appropriate, we calculated positive and
negative predictive values (PPVs and NPVs) and their
95 % CIs using the Wilson binomial method [20].
Pearson’s correlation coefficient (or Spearman’s rank
correlation coefficient for ordinal variables) and 95 % CI
were calculated based on Fisher’s r-to-z transformation
to assess presence of linear relationship between con-
tinuous variables. Bland Altman plots [21] were con-
structed for quantifying inter-observer agreement. The
Bland Altman method evaluates a bias (accuracy) be-
tween the mean differences of two quantitative mea-
sures, and an agreement interval (mean ± 1.96 standard
deviation) within which 95 % of the differences fall (pre-
cision). Were the assumption of normal distribution of
differences not satisfied (Graphical inspection of histo-
gram, or P < .05 in Shapiro-Wilk test for normality), the
fold empirical cumulative distribution plot (mountain
plot) was used instead. The center of the mountain plot
shows the median bias between the measures, while its
tails show the propensity for the new method to deviate
significantly from the comparison method [22].
Questionnaire construct validity was estimated by the
strength of correlation between self-reported chronic
pain intensity and self-reported number of pain loca-
tions. Chronic pain intensity was rated on a 10-likert
scale as 0 = no and 10 = unendurable pain, while number
of pain locations ranged from 0 to 4 (area of the oper-
ated breast, armpit, arm, body side). Similarly, the
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validity of reporting on employment transition was esti-
mated by assessing its correlation with self-reported in-
come instability following breast cancer diagnosis/
treatment. Employment transition or income instability
was categorized as 1 = no change or stable, 2 = upgraded
(from part-time to full-time job, or from not working to
part/full-time job) or increased, and 3 = downgraded
(from full-time to part-time job or not working/retired,
or from part-time job to not working/retired) or de-
creased, respectively. The internal consistency of the SF-
36 subscales was analyzed using Cronbach’s alpha with
minimum acceptable value of alpha set to 0.7. T-test was
performed to determine significant differences in quality
of life scores between cancer survivors and the general
population.
Completeness of data elements in administrative data-
bases (LHS and INCR) or the self-report questionnaire
was calculated as a proportion of total study subjects (n
= 119) or total respondents (n = 67), respectively. Associ-
ation between accuracy of self-reported medical history
and potential explanatory self-reported variables, includ-
ing age at time of survey, breast cancer diagnosis year,
cohabitation status (married/unmarried), ethnicity
(Jews/Arabs), immigration status (yes/no), parity, num-
ber of education years attained, family medical history of
cardiovascular disease or diabetes (yes/no), body mass
index (BMI), and lifestyle behaviors of physical activity,
smoking and healthy diet (yes/no), was appraised using
logistic regression with responses classified as correct or
incorrect relative to LHS medical records. Odds ratios
(ORs) and 95 % CIs were calculated. Due to the rela-
tively small sample size, cohabitation status and lifestyle
behavior variables were dichotomized: Unmarried cat-
egory comprised of all women not married (single, sepa-
rated, widowed, or divorced), former smoker was
considered as nonsmoker, and the frequency of fruits
and vegetables consumption originally rated on an or-
dinal scale was converted to a dichotomous variable with
daily servings ≥1 regarded as eating healthy diet.
Statistical significance was defined as a two-tailed P <
0.05. All statistical analyses were performed using SAS
9.2 (SAS Institute Inc., Cary, NC, USA) and MedCalc
15.10.1 (MedCalc Software, Ostend, Belgium).
The Institutional Review Boards of LHS and University
of Haifa approved the research protocol and all partici-
pants provided oral informed consent.
Results
Of the 119 women identified from LHS databases as cor-
rectly having a diagnosis of breast cancer, 83 patients met
the inclusion criteria. A dataset summarizing characteris-
tics of the 83 survivors was created based on information
synthesized from administrative databases, medical re-
cords, and the questionnaire (which contributed features












• Evidence of angina pectoris
symptoms or acute coronary
syndrome, and/or




• EF < 40 %, and/or
• ≥3 dispensed prescriptions of
diuretics, ACEI/ARB, or digoxin
within six months following










• ≥3 dispensed prescriptions of
antiarrhythmic agents within
6 months following event
Stroke
(430–438)
• Hospitalization discharge sheet
indicating a cerebral event, and/
or
• Imaging report (CT, PET, MRI),
and/or
• ≥3 dispensed prescriptions of
anticoagulant agents within
6 months following event
Fractures
(800–829)
• Imaging report (radiographs),
and/or
• Orthopedic referrals
• Operations on the
musculoskeletal system (ICD-9
codes 76–84)




• Bone mineral density (T-score≤
−2.5) [37], and/or
• ≥1 dispensed prescriptions of
bisphosphonates or estrogen
agonist/antagonist (raloxifene)
within 1 year following event
Diabetes
(250)
• HbA1c level ≥6.5 %, or FPG≥
126 mg/dL, or 2-hour PG
≥200 mg/Dl [38], and/or
• ≥3 dispensed prescriptions of
insulin and oral diabetes
medications within 6 months
following diabetes diagnosis
Chronic painb • Concordance with the Hebrew
validated Short Form 36 (SF-36)
[17]
Abbreviations: ICD-9 International Classification of diseases, Ninth Revision, EF
ejection fraction, ACEI angiotensin converting enzyme inhibitor, ARB
angiotensin receptor blocker, CT computerized tomography, PET positron
emission tomography, MRI magnetic resonance imaging, HbA1c hemoglobin
A1C, FPG fasting plasma glucose, 2-PG 2-hour post glucose‑load
plasma glucose
a To account for possible variance in physician interpretation of ICD-9 codes
and to increase the sensitivity of this tool, the current study referred only to
the first three digits of ICD code for disease diagnosis [39], except for osteo-
porosis, which is a specific disorder of bone and cartilage
b Chronic pain defined as pain persisting 3 months, beyond the normal time
of healing [40]
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of only alive women at time of survey) according to the
aforementioned validation procedure. The mean age at
diagnosis was 57 years for Jewish women and 50 years for
Arab women (Table 2). Jewish women were more edu-
cated, less parous and reported chronic pain intensity to a
lesser extent than their Arab counterparts. Distribution of
combinations of treatments among these patients yielded
four main mutually exclusive treatment categories that
could be utilized in defining the exposure parameter in
the full-scale study (Fig. 2). There were no significant dif-
ferences in terms of breast cancer diagnosis year, age at
diagnosis and treatments between the study population
and the 67 interviewees (data not shown).
Completeness and agreement between data sources
Agreement analysis was carried out on the initial study
population (119 breast cancer patients) in order to de-
tect all discrepancies between research tools, some of
which were liable to disappear following the exertion of
inclusion criteria. In the full-scale study, we will perform
sensitivity analyses of inclusion criteria in order to inves-
tigate the validity and robustness of the findings and
conclusions, and therefore, information must be valid
for all breast cancer survivors, regardless of compatibility
to eligibility criteria. Table 3 displays concordance and com-
pleteness results for categorical parameters. Except for co-
habitation status, the agreement and predictive values on
demographics were significantly very good. In regard to
breast cancer characterization and treatment, LHS agreed
very well with INCR on breast cancer laterality and type of
surgery (Kappa ≥ 0.84), but moderately on axillary node
dissection. Agreement on adjuvant therapy was calculated
for two periods with 2003 set as the cut-off point, for in this
year LHS completed the establishment of organized elec-
tronic claims. Unlike the low PPVs during the period before
2003, PPVs in years 2003–2010 were above 85 %. The
agreement on reported personal medical history with chart
review was mostly fair to moderate. The NPVs were almost
perfect, translated to low false negatives, whereas the low
PPVs indicated high false positive reporting.
Agreement between data sources on continuous vari-
ables was quantified graphically (Fig. 3). Generally, the
data sources were highly correlated (P < .001), and the
plots demonstrated good agreement between them. Bias
between INCR and LHS was nearly zero on age at diag-
nosis, however the tails were large and skewed to the left
(Fig. 3a). In contrast, the 95 % tails of the mountain plot
analysis between INCR and the questionnaire on year of
diagnosis, an equivalent parameter to age at diagnosis,
were only ±1 from the median (Fig. 3b). Bland Altman
plot showed a slight bias (0.5 kg/m2) and uniform distri-
bution of the variances over most of the measured BMIs.
Despite that the self-reported weight or height were
within the acceptably ±2.0 kg or ±2.0 cm measured
weight or height, respectively, the limits of agreement of
BMI were wider than the acceptable well-established
limits of ±1.4 kg/m2 (Fig. 3c) [23].
LHS claims databases were almost complete, missing
information was mainly confined to the period before
2003. INCR database had markedly missing information
on adjuvant therapy, whereas data elicited from the
questionnaire were 100 % complete (Table 3, Fig. 3).
Validity of LHS outcome diagnosis coding
LHS administrative databases recorded the diagnosis
correctly in most times (≥94 % proportion correct).
Agreement with medical records was good for stroke,
and very good for all other outcomes. Generally, NPVs
were higher than PPVs. Incidence of fractures and most
cardiovascular events was low (≤10 %), whereas chronic
pain was mildly to severely experienced by more than
half of the questionnaire participants (Table 4).
Predictors of the accuracy of self-reported personal med-
ical history
In multivariable analysis of factors likely to be associated
with agreement between the self-reported medical his-
tory of hypertension and chart review, only year of
breast cancer diagnosis was significant (P = .020). Sub-
jects were more likely to correctly report hypertension
the more recently in time that their breast cancer had
been diagnosed (OR, 1.61; 95 % CI, 1.08–2.41). Family
history of cardiovascular disease predicted correct
reporting of hyperlipidemia (OR, 5.12; 95 % CI, 1.21–
21.65; P = .026). Increasing levels of BMI were associated
with better reporting as well and almost reached statis-
tical significance (OR, 1.21; 95 % CI, 0.99–1.48; P
= .057). Correct reporting of osteoporosis was signifi-
cantly associated with ethnic disparities. Jewish women
were more likely to accurately report diagnosis of osteo-
porosis than Arab women (OR, 25.30; 95 % CI, 1.48–
433.61; P = .026). In contrast, increasing number of off-
spring (parity) was significantly associated with incorrect
responses regarding osteoporosis (OR, 0.60; 95 % CI,
0.38–0.95; P = .029).
Questionnaire pretest and validity
Questionnaire administration to all respondents spread
over a two-month period. All the participants who com-
pleted the survey found it acceptable, and did not refuse
to answer any question, although such choice was pro-
vided. Language-wise, there were no problems of under-
standing the content of questions, although some Arab
women needed at times translation, especially of diagno-
ses. We only revised the question on location of chronic
pain, since despite respondents were instructed to select
only one answer per question, they frequently pointed to
more than one location.
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Table 2 Characteristics of the study population, by ethnicity
Characteristic Breast cancer patients (n = 83, 100 %)a
Jewish women
(n = 54, 65.1 %)
Arab women




≤ 39 years 2 (3.7) 8 (27.6)
40–49 years 13 (24.1) 8 (27.6)
50–59 years 21 (38.9) 8 (27.6)




27 (50.0) 15 (51.7)
Unmarriedb 18 (33.3) 7 (24.1)
Missingc 9 (16.7) 7 (24.1)
Education,
meand (SD), year




34 (63.0) 1 (3.4)
No (country
birth Israel)
11 (20.4) 21 (72.4)
Missing 9 (16.7) 7 (24.1)
Parity
0 2 (3.7) 3 (10.3)
1 12 (22.2) 0 (0.0)
2 16 (29.6) 2 (6.9)
3 9 (16.7) 2 (6.9)
≥ 4 6 (11.1) 15 (51.7)





2003–2005 21 (38.9) 8 (27.6)
2006–2008 18 (33.3) 12 (41.4)
2009–2010 15 (27.8) 9 (31.0)
Treatments
Breast conserving 41 (75.9) 18 (62.1)
Mastectomy 12 (22.2) 10 (34.5)
Axillary lymph
node dissection
32 (59.3) 21 (72.4)
Radiotherapy 48 (88.9) 27 (93.1)
Chemotherapye 28 (51.9) 23 (79.3)




No change 25 (46.3) 17 (58.6)
Table 2 Characteristics of the study population, by ethnicity
(Continued)
Upgraded 1 (1.9) 0 (0.0)
Downgraded 19 (35.2) 5 (17.2)
Missing 9 (16.7) 7 (24.1)
Income change following
diagnosis/treatment
No change 26 (48.2) 17 (58.6)
Increased 0 (0.0) 1 (3.5)
Decreased 19 (35.2) 4 (13.8)
Missing 9 (16.7) 7 (24.1)
Weight change following
diagnosis/treatment
No change 15 (27.8) 8 (27.6)
Increased 16 (29.6) 11 (37.9)
Decreased 13 (24.1) 3 (10.3)
Don’t know 1 (1.9) 0 (0.0)
Missing 9 (16.7) 7 (24.1)
Chronic pain related
to breast cancer
Yes 31 (57.4) 19 (65.5)
No 14 (25.9) 3 (10.3)
Missing 9 (16.7) 7 (24.1)
Chronic pain intensity
0 (no pain) 14 (25.9) 3 (10.3)
1–3 (light pain) 5 (9.3) 3 (10.3)
4–7 (moderate pain) 26 (48.2) 10 (34.5)
8–10 (severe pain) 0 (0.0) 6 (20.7)
Missing 9 (16.7) 7 (24.1)
Number of chronic
pain locations
0 14 (25.9) 3 (10.3)
1–2 24 (44.4) 9 (31.0)
3–4 7 (13.0) 10 (34.5)
Missing 9 (16.7) 7 (24.1)
Lifestyles
Tobacco use
Current smoker 7 (13.0) 2 (6.9)
Former smoker 7 (13.0) 1 (3.5)
Never smoker 31 (57.4) 19 (65.5)
Missing 9 (16.7) 7 (24.1)
Physical activity
Yes 33 (61.1) 13 (44.8)
No 12 (22.2) 9 (31.0)
Missing 9 (16.7) 7 (24.1)
Daily servings of fruits
and vegetables
0 0 (0.0) 0 (0.0)
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Chronic pain intensity positively correlated with num-
ber of pain locations (Spearman correlation coefficient,
0.83; 95 % CI, 0.73–0.89; P < .001). In a similar manner
but to a lesser extent, employment transition correlated
with income instability (Spearman correlation coeffi-
cient, 0.7; 95 % CI, 0.56–0.81; P < .001).
Table 5 provides the SF-36 subscale reliability scores.
Cronbach’s alpha coefficients ranged from 0.9 to 1.0,
meeting the acceptable level of scale reliability [24].
Except for subscales of general health and physical
functioning, the correlations of items with their scales
exceeded 0.5. When comparing mean scores of
health-related quality of life with the general adult
Hebrew-speaking population [17], our sample popula-
tion was significantly associated with worse health
assessment, expressed in lower scores on all eight
subscales.
Discussion
Agreement among administrative databases and self-
report constructed questionnaire ranged from moderate
to very good. In general, the study data sources highly
agreed on patient demographics, with the exception of
cohabitation status for which the majority of inaccur-
acies were LHS misclassification of divorced/widowed
women as being married. This may allude to lack of
streamlined update of marital status in LHS databases,
but may also reflect the dynamics of marital dissolution
and social support deprivation due to illness.
LHS administrative claims databases proved to be ac-
curate in regard to adjuvant therapy as beginning from
2003 onward, and can be readily used for adjuvant care
surveillance without extensive validation. The low agree-
ment with INCR on axillary node dissection and the
slight disagreement on type of surgery render INCR as
the preferable method for capturing surgical treatment
information, consistent with findings by Turner and col-
leagues [25].
There were knowledge gaps among breast cancer sur-
vivors concerning their medical history, varying by con-
dition and patient characteristics. In accordance with
previous reports [26, 27], agreement with medical re-
cords ranged largely from fair to good. However, results
must be dealt with caution as Kappa, much like predict-
ive values, is affected by prevalence of the finding under
consideration [28]. In general, women overreported co-
morbidities. The association between recency of breast
cancer diagnosis and correctly-reported hypertension
could be attributed to the ongoing management of
treatment-related symptoms and side effects [7], and
more frequent physician visits. Routine measurement of
blood pressure during these visits is considered a quality
care since hypertension is not only a comorbidity but a
risk factor for cardiovascular disease, and therefore
Table 2 Characteristics of the study population, by ethnicity
(Continued)
1–2 28 (51.9) 18 (62.1)
≥ 3 17 (31.5) 4 (13.8)
Missing 9 (16.7) 7 (24.1)
BMI, mean (SD), kg/m2 27.4 (4.9) 29.5 (6.3)
Abbreviations: SD standard deviation, BMI body mass index
a 83 Eligible participants identified by both LHS and INCR records; of them 67
completed the survey questionnaire. Data are presented as No.(%) unless
otherwise noted; percentages may not sum to 100 due to rounding
b Unmarried category comprised of all women not married: divorced,
separated, widowed, or single
c Missing information refers to information elicited from questionnaires, since
not all subjects were interviewed
d Analysis of mean education did not include missing data of 16 subjects who
were not interviewed
e Chemotherapy comprised mainly of anthracycline or
taxane-based combinations
f Hormone therapy was based on aromatase inhibitors, anti-estrogens,
or combinations
Fig. 2 Distribution of treatments among 83 one-year breast cancer survivors. Notations: Rx, radiotherapy; Chem, chemotherapy; Hormone, hor-
mone therapy. The proportions do not sum 100 % because more rare combinations of treatment (i.e., surgery only; etc.) are not presented
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Table 3 Validity and completeness of patient categorical features across data sources




INCR LHS QUES Proportion
correct % (n)
Kappa (n, 95 % CI)a PPV (95 % CI) NPV (95 % CI) INCR LHS QUES
Demographics Residence —— ✓ ✓ QUES 100 (67) —— 100 (94.6–100) —— —— 100 (119/119) 100 (67/67)
Ethnicity ✓ —— ✓ QUES 100 (62) 1 (62) 100 (91.2–100) 100 (85.1–100) 92.4 (110/119) —— 100 (67/67)
Cohabitation
status
—— ✓ ✓ QUES 60.9 (46) 0.55 (46, 0.33–0.76) 71.1 (55.2–83) 12.5 (2.2–47.1) —— 73.1 (87/119) 100 (67/67)




Laterality ✓ ✓ —— INCR 97.8 (89) 0.95 (89, 0.89–1) 97.3 (86.2–99.5) 98.1 (89.9–99.7) 96.6 (115/119) 75.6 (90/119) ——
Surgery ✓ ✓ —— INCR 100 (97) —— 100 (96.2–100) —— 81.5 (97/119) 97.5 (116/119) ——
Breast
conserving surgery
✓ ✓ —— INCR 93.8 (97) 0.86 (97, 0.75–0.97) 98.4 (91.5–99.7) 85.3 (69.9–93.6) 81.5 (97/119) 94.1 (112/119) ——
Mastectomy ✓ ✓ —— INCR 92.8 (97) 0.84 (97, 0.72–0.95) 91 (81.8–95.8) 96.7 (83.3–99.4) 81.5 (97/119) 94.1 (112/119) ——
ALN dissection ✓ ✓ —— INCR 79.4 (97) 0.50 (97, 0.33–0.67) 75.3 (64.9–83.4) 100 (80.6–100) 81.5 (97/119) 92.4 (110/119) ——
Radiotherapy
Before 2003 ✓ ✓ —— LHS claims 28.6 (7) —— 28.6 (8.2-64.1) —— 26.9 (7/26) 34.6 (9/26) ——
2003-2010 ✓ ✓ —— LHS claims 87.5 (8) —— 87.5 (52.9-97.8) —— 8.6 (8/93) 100 (93/93) ——
Chemotherapy
Before 2003 ✓ ✓ —— LHS claims 44.4 (9) —— 44.4 (18.9-73.3) —— 34.6 (9/26) 46 (12/26) ——
2003-2010 —— LHS claims 91.7 (12) —— 91.7 (64.6-98.5) —— 12.9 (12/93) 100 (93/93) ——
Hormone therapy
Before 2003 ✓ ✓ —— LHS claims 0 (1) —— 0 (0–79.4) —— 3.8 (1/26) 65 (17/26) ——
2003-2010 ✓ ✓ —— LHS claims 100 (5) —— 100 (56.6-100) —— 5.4 (5/93) 100 (93/93) ——
Personal medical
history
Hypertension —— ✓ ✓ Medical record 79.1 (67) 0.55 (67, 0.36-0.74) 51.7 (34.4-68.6) 100 (90.8-100) —— 100 (119/119) 100 (67/67)
Hyperlipidemia —— ✓ ✓ Medical record 73.1 (67) 0.46 (67, 0.25-0.66) 59.4 (42.3-74.5) 85.7 (70.6-93.7) —— 100 (119/119) 100 (67/67)
Renal failure —— ✓ ✓ Medical record 100 (67) —— —— 100 (94.6-100) —— 100 (119/119) 100 (67/67)
Rheumatoid
arthritis
—— ✓ ✓ Medical record 97 (67) 0.65 (67, 0.21-1) 50 (15–85) 100 (94.3-100) —— 100 (119/119) 100 (67/67)
Diabetes —— ✓ ✓ Medical record 97 (67) 0.93 (67, 0.83-1) 90.5 (71.1-97.4) 100 (92.3-100) —— 100 (119/119) 100 (67/67)
Osteoporosis —— ✓ ✓ Medical record 68.7 (67) 0.37 (67, 0.14-0.59) 67.9 (49.3-82.1) 69.2 (53.6-81.4) —— 100 (119/119) 100 (67/67)
Abbreviations: INCR Israel National Cancer Registry, LHS Leumit Health Services, QUES questionnaire, CI confidence interval, ALN axillary lymph node















physicians are continually reminded to raise the patient
awareness of their medical condition and to emphasize
the benefits of strict adherence to hypertensive medica-
tions. Similarly, the positive association between
correctly-reported hyperlipidemia and family history of
cardiovascular disease or increasing BMI levels may be
explained by the fact that women with established risk
factors for heart disease are monitored closely for high
levels of cholesterol [29]. The accuracy of self-reported
osteoporosis was the lowest of all comorbidities; the
Kappa statistic of 0.37 was comparable to that reported
by Stuart and colleagues [30]. Reporting inaccuracy may
be attributed to patient misunderstanding of their bone
mineral density (BMD) test results [30], often misclassi-
fying osteoporosis with osteopenia [31]. Jewish women
were less likely to misclassify osteoporosis than Arab
women. Ethnicity could be a surrogate for level of edu-
cation; Jewish women in our sample were more educated
than Arab women (Table 2), and could discern osteope-
nia from osteoporosis more easily. Alternatively, ethni-
city could reflect language barriers that hinder Arab
women from understanding the term “osteoporosis”.
Parity was associated with reduced ability to correctly
report osteoporosis as well. Parity may be linked to pro-
longed lactation period and inadequate recovery of bone
calcium [32]. Parous women who subsequently initiate
on calcium supplement intake to replenish their body
supply may misperceive their condition as osteoporotic.
Self-reported date of breast cancer diagnosis was not
biased and was largely within the 95 % agreement limits
with INCR. This accuracy could be attributed to subject-
ive perceived importance of the matter [33]. Self-
Fig. 3 Validity and completeness of patient continuous features across data sources: a, Mountain plot analysis of agreement between INCR and
LHS on age at breast cancer diagnosis. Median = (−0.04y), percentiles: 2.5th = (−9.2y) 97.5th = 0.2y; b, Mountain plot analysis between INCR and
questionnaire on breast cancer diagnosis year. Median = 0y, percentiles: 2.5th = (−1y) 97.5th = 1y; c, Bland Altman analysis of agreement between
LHS and QUES on body mass index (BMI). The mean BMI difference = 0.5 kg/m2 (mean weight and height difference, 0.9 kg and 0.6 cm,
respectively), and the 95 % limits of agreement from −2.3 kg/m2 to 3.3 kg/m2 (Measured BMI was up to one year from self-reported BMI)
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assessment of chronic pain was also shown to be accur-
ate. This is a finding of paramount importance, since
when we compared the proportion of women who re-
ported not having chronic pain with painkillers procure-
ment history retrieved from LHS pharmacy claims (a
proxy measure for chronic pain), only 6 % of women
reporting not having chronic pain did not consume
painkillers, rendering administrative databases as unsuit-
able for assessment of chronic pain.
Outcome diagnosis abstracted from administrative
databases exhibited high concordance with medical
records. Therefore, it is warranted to use LHS data-
sets to abstract information on diseases and to drop
relevant questions from the questionnaire, with reser-
vations on breast cancer diagnosis date. Notwith-
standing the accurate identification of breast cancer
cases in LHS databases as compared to INCR (PPV,
99; 95 % CI, 95.4-99.9), diagnosis dates were occa-
sionally incomparable; often INCR preceding LHS. A
reasonable explanation of such discrepancy may be
embedded in the coding conundrum of active versus
history of cancer [34]. As long as breast cancer pa-
tients receive treatment for the condition, they con-
tinue to be reported with the malignant neoplasm
ICD-9 code 174. Only when the malignancy has been
excised, there is no ongoing treatment, and there is
no evidence of recurrence, the code is replaced with
V10.3, personal history of malignant neoplasm of
breast. By reason of the extended period of receiving
adjuvant therapy, breast cancer cases identified in
LHS registry during 2000 and 2010 as active could
lag to an earlier period. Another probable explanation
could be attributed to the fact that INCR registers
the date of the pathological report as the date of
diagnosis while the HMO may use instead the date of
treatment initiation. It is, therefore, necessary to com-
pare LHS and INCR breast cancer diagnosis dates be-
fore commencing on the full-scale study. An easier
approach would be identifying patients directly from
INCR then linkage with LHS databases; however,

















Cardiovascular disease 119 Medical record 20.2 98.3 0.95 (0.88-1) 95.8 (79.8-99.3) 99 (94.3-99.8) 100 (119/119)
Ischemic heart disease 119 Medical record 15.1 98.3 0.93 (0.84-1) 94.4 (74.2-99) 99 (94.6-99.8) 100 (119/119)
Congestive heart failure 119 Medical record 2.5 100 1 100 (43.9-100) 100 (96.8-100) 100 (119/119)
Conduction disorders and
cardiac dysrhythmias
119 Medical record 8.4 99.2 0.94 (0.83-1) 100 (70.1-100) 99.1 (95–99.8) 100 (119/119)
Stroke 119 Medical record 7.6 97.5 0.79 (0.55-1) 100 (61–100) 97.4 (92.5-99.1) 100 (119/119)
Fractures 119 Medical record 6.7 98.3 0.85 (0.64-1) 100 (61–100) 98.2 (93.8-99.5) 100 (119/119)
Osteoporosis 119 Medical record 25.2 98.3 0.96 (0.90-1) 93.8 (79.9-98.3) 100 (95.8-100) 100 (119/119)
Diabetes 119 Medical record 15.1 99.2 0.97 (0.91-1) 94.8 (75.4-99.1) 100 (96.3-100) 100 (119/119)
Chronic pain 67 SF-36 68.7a 94 0.85 (0.72-0.99) 92 (81.2-96.9) 100 (81.6-100) 100 (67/67)
Abbreviations: PPV, positive predictive value; NPV, negative predictive value; CI, confidence interval; SF-36, 36-item short form
a For chronic pain, the effect measure is prevalence
Table 5 Reliability of SF-36 form self-reported data
SF-36 Health
Form Subscales











Bodily pain 0.9 2 0.9 <.001 63.7 23.9 71.6 29.8 .01
General health 0.9 5 0.4–0.8 <.001 49.0 31.0 62.9 23.8 <.001
Mental health 0.9 5 0.5–0.7 <.001 54.5 28.7 67.1 21.7 <.001
Physical functioning 0.9 10 0.1–0.8 <.001–0.376 59.8 40.0 77.3 26.6 <.001
Role emotional 1.0 3 1.0 <.001 50.7 50.1 81.1 35.7 <.001
Role physical 1.0 4 0.8–1.0 <.001 49.3 50.1 71.3 40.8 <.001
Social functioning 0.9 2 0.8 <.001 59.5 27.2 81.8 26.8 <.001
Vitality 0.9 4 0.7–0.9 <.001 39.3 25.8 56.9 22.8 <.001
Abbreviations: SF-36, 36-item short form, Sig significance, SD standard deviation
a Correction refers to recoding per a scoring key [12]
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INCR is prohibited from releasing information unless
provided with a list of patients and an ethics approval
from the care provider.
The questionnaire was demonstrated as approvingly
valid. The uniform distribution of BMI variances despite
the slight wider limits of agreement than the acceptable,
the high internal consistency of the quality-of-life sub-
scales, and the large correlation between self-reported
pain intensity and number of pain locations or employ-
ment transition and income instability, altogether bestow
reported information highly-ranked credibility.
Common sense suggests that the shorter the question-
naire, the more likely a high response rate. Surprisingly,
not only 99 % of contacted women responded, but they
willingly provided complete information. We conjecture
that personal contact greatly increased participation rate.
Other strengths of this feasibility study include the two-
stage pretest of the survey, the definitive validation algo-
rithms of outcomes using the medical records as the ref-
erence standard, exploration of potential factors
associated with agreement, and almost complete infor-
mation in LHS administrative databases, the main data
source of the study.
The external generalizability of the study results to all
Israeli female survivors of breast cancer might be af-
fected, inasmuch LHS is the smallest of four Israeli not-
for-profit HMOs. Despite, as previously reported [14],
all HMOs are obliged to insure every applicant regard-
less of age, gender, health condition, or any other criter-
ion, LHS approach to data collection and management
may differ from other HMOs, and thus the validity of
administrative information might not be generalizable
after all to other care funds. Further research comparing
cancer care data quality among Israeli HMOs is, there-
fore, warranted. On the other hand, it is unlikely that
breast cancer patients in LHS differ fundamentally from
other breast cancer survivors, and therefore, the study
conclusions regarding the validity of self-report may be
generalized to all breast cancer survivors.
Another shortcoming of this feasibility study is poten-
tial selection bias by limiting the sample to women
treated within a single institution. As one of our objec-
tives was to examine heterogeneity of treatment, we
needed to isolate effect of inter-institution variance in
treatment protocol; therefore, we selected one institution
which offered all treatments. Additionally, women re-
cruited were oversampled for Arab minority; this could
have affected generalizability of results and agreement
inasmuch the likelihood of correct responses was associ-
ated with ethnic disparities. Nevertheless and more im-
portantly, the principal intention of this pilot study was
to evaluate the impact of language barriers on compre-
hension capabilities of a Hebrew-written questionnaire,
which, in our opinion, outweighs this drawback.
Additional study limitations include the small sample
size as is common for a feasibility study [35]. Although
this sample size was sufficient for providing information
about all investigated aspects, it might have lacked stat-
istical power, and significant results could perhaps be
corollary of chance, which could explain the broad confi-
dence intervals around the estimates.
Our study may have important implications on health
policy and clinical practice. Health policy regulators rely
substantially on the data produced by clinical research
studies to base their informed decisions and institute cost-
effective guidelines that affect clinical practice. Policy deci-
sions, such as resource allocation, reimbursement, preven-
tion, surveillance, implementation of health education and
promotion activities or disease management programs,
however, must stem from valid and credible information,
otherwise they may be biased, inefficacious, and may incur
expenses that do not benefit either the public or the health
care systems, specifically at times of increasingly economic
constraint and cost-containment policies. The high quality
and integrity of administrative data demonstrated in this
study, diagnoses in particular, ensure that these ready-to-
use automated information delivery systems can be relied
upon and utilized to evaluate cancer treatment late effects
and promote policies of survivorship care. Furthermore,
the remarkable accuracy of administrative claims treat-
ment and outcome information gives them an edge over
the expensive and time-consuming medical records, and
sets them as the preferable data source at the policy level.
Conclusions
The results of this feasibility study demonstrate that in the
absence of a national registry for cancer care, a mixed
methodology for data collection provides the most
complete information: accessing details of adjuvant ther-
apy, medical history and outcomes from HMO adminis-
trative databases, collecting data on initial treatment by
linkage with cancer registries, and interviewing patients
for the added value of lifestyle behavior and subjective ap-
praisal of quality of life. Such an approach is likely to be
more comprehensive than collecting patient features by
abstraction from individual medical records. The accurate
self-assessment of chronic pain should be of use to other
researchers who are considering using self-report ques-
tionnaires to determine the impact of cancer treatment on
chronic pain and related sequelae. Finally, designing me-
ticulous validation schemes and careful piloting are critical
for identifying potential flaws and bias in research instru-
ments before launching on a large-scale study which will
require data abstraction and participation of breast cancer
patients of much larger dimensions.
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